1-20 of 21
William B. Donnellan
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Olutasidenib Alone or in Combination with Azacitidine Induces Durable Complete Remissions in Patients with mIDH1 Myelodysplastic Syndromes/Neoplasms (MDS)

Jorge Cortes, Jay Yang, Sangmin Lee, Shira N. Dinner, Eunice S. Wang, Maria R. Baer, William B. Donnellan, Justin M. Watts
Journal: Blood
Blood (2023) 142 (Supplement 1): 1872.
https://doi.org/10.1182/blood-2023-187404
Published: 2023
Journal Articles

Factors Impacting Response to Olutasidenib in Patients with mIDH1 Acute Myeloid Leukemia

Eunice S. Wang, Brian A. Jonas, Justin M. Watts, Joseph Jurcic, P. Brent Ferrell, Jr., Shira N. Dinner, Jay Yang, Karen Seiter, Alice Mims, William B. Donnellan, William Blum, Jorge Cortes
Journal: Blood
Blood (2023) 142 (Supplement 1): 6047.
https://doi.org/10.1182/blood-2023-187584
Published: 2023
Journal Articles

KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results

Clinical Trials & Observations
Bijal D. Shah, Michael R. Bishop, Olalekan O. Oluwole, Aaron C. Logan, Maria R. Baer, William B. Donnellan, Kristen M. O’Dwyer, Houston Holmes, Martha L. Arellano, Armin Ghobadi, John M. Pagel, Yi Lin, Ryan D. Cassaday, Jae H. Park, Mehrdad Abedi, Januario E. Castro, Daniel J. DeAngelo, Adriana K. Malone, Raya Mawad, Gary J. Schiller, John M. Rossi, Adrian Bot, Tong Shen, Lovely Goyal, Rajul K. Jain, Remus Vezan, William G. Wierda
Journal: Blood
Blood (2021) 138 (1): 11–22.
https://doi.org/10.1182/blood.2020009098
Published: 2021
Includes: Supplemental data
Journal Articles

Center Effects on Outcomes in the Treatment of Acute Myelogenous Leukemia (AML): A Multilevel, Community-Based, Case-Controlled Study

Charles F. Lemaistre, MD, Ju-Hsien Chao, DO, Tonya Cox, BSN, RN, Jose Carlos Cruz, MD, William B. Donnellan, MD, Alireza Eghtedar, MD, Jared Holder, MA, Suman Kambhampati, MD, Shahbaz Malik, Michael B. Maris, MD, Marcello Rotta, MD, Frank Thomas Slovick, MD, Minoo Battiwalla, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4780.
https://doi.org/10.1182/blood-2019-130640
Published: 2019
Journal Articles

The First-in-Class Anti-CD47 Antibody Magrolimab (5F9) in Combination with Azacitidine Is Effective in MDS and AML Patients: Ongoing Phase 1b Results

David A Sallman, MD, Adam S. Asch, MD, Monzr M. Al Malki, MD, Daniel J. Lee, MD, William B. Donnellan, MD, Guido Marcucci, MD, Suman Kambhampati, MD, Naval G. Daver, MD, Guillermo Garcia-Manero, MD, Rami S. Komrokji, MD, Joanna Van Elk, Ming Lin, PhD, Jens-Peter Volkmer, MD, Chris H Takimoto, MD PhD, Mark Chao, MD PhD, Paresh Vyas, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 569.
https://doi.org/10.1182/blood-2019-126271
Published: 2019
Journal Articles

Olutasidenib (FT-2102) Induces Rapid Remissions in Patients with IDH1-Mutant Myelodysplastic Syndrome: Results of Phase 1/2 Single Agent Treatment and Combination with Azacitidine

Jorge E. Cortes, MD, Eunice S. Wang, MD, Justin M. Watts, MD, Sangmin Lee, MD, Maria R. Baer, MD, Kim-Hien Dao, DO, PhD, Shira Dinner, MD, Jay Yang, MD, William B. Donnellan, MD, Anthony P Schwarer, MD MBBS (Hons), FRACP, FRCPA, Christian Recher, MD PhD, Patrick Kelly, MD, Jennifer Sweeney, Julie Brevard, Patrick Henrick, Sanjeev Forsyth, Sylvie Guichard, Hesham Mohamed, MD, Andrew H. Wei, PhD FRACP, FRCPA, MBBS
Journal: Blood
Blood (2019) 134 (Supplement_1): 674.
https://doi.org/10.1182/blood-2019-124360
Published: 2019
Journal Articles

Results of a Clinical Trial of H3B-8800, a Splicing Modulator, in Patients with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML)

David P. Steensma, MD, Martin Wermke, MD, Virginia M. Klimek, MD, Peter L Greenberg, MD, Patricia Font, Rami S. Komrokji, MD, Jay Yang, MD, Andrew M. Brunner, MD, Hetty E. Carraway, MD MBA, Lionel Ades, MD PhD, Aref Al-Kali, MD, Juan Manuel Alonso Dominguez, MD PhD MSc, Ana Alonso, MD, Catherine C. Coombs, MD, H. Joachim Deeg, MD, William B. Donnellan, MD, James M. Foran, MD, Guillermo Garcia-Manero, MD, Michael B. Maris, MD, Malgorzata McMasters, MD, Jean-Baptiste Micol, MD, Jaime Perez De Oteyza, MD PhD, Felicitas Thol, MD, Eunice S. Wang, MD, Justin M. Watts, MD, Silvia Buonamici, PhD, Amy Kim, MSPh PhD, Vikram Gourineni, MS, PharmD, Alyssa J Marino, Nathalie Rioux, MSc, PhD, Joanne Schindler, MD, Sherri Smith, MS, Huilan Yao, PhD, Xiaobin Yuan, Kun Yu, PhD, Uwe Platzbecker
Journal: Blood
Blood (2019) 134 (Supplement_1): 673.
https://doi.org/10.1182/blood-2019-123854
Published: 2019
Journal Articles

Olutasidenib (FT-2102), an IDH1m Inhibitor As a Single Agent or in Combination with Azacitidine, Induces Deep Clinical Responses with Mutation Clearance in Patients with Acute Myeloid Leukemia Treated in a Phase 1 Dose Escalation and Expansion Study

Justin M. Watts, MD, Maria R. Baer, MD, Jay Yang, MD, Thomas Prebet, MD PhD, Sangmin Lee, MD, Gary J. Schiller, MD, Shira Dinner, MD, Arnaud Pigneux, Pau Montesinos, MD PhD, Eunice S. Wang, MD, Karen Seiter, MD, Andrew H. Wei, PhD FRACP, FRCPA, MBBS, Stephane De Botton, Montserrat Arnan Sangerman, William B. Donnellan, MD, Brian A Jonas, MD PhD, Paul Brent Ferrell, Jr., MD, Kim-Hien Dao, DO, PhD, Patrick Kelly, MD, Jennifer Sweeney, Sanjeev Forsyth, Sylvie Guichard, Julie Brevard, Patrick Henrick, Hesham Mohamed, MD, Jorge E. Cortes, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 231.
https://doi.org/10.1182/blood-2019-123920
Published: 2019
Journal Articles

A Phase I/II Study of AZD2811 Nanoparticles (NP) As Monotherapy or in Combination in Treatment-Naïve or Relapsed/Refractory AML/MDS Patients Not Eligible for Intensive Induction Therapy

William B. Donnellan, MD, Ehab L. Atallah, MD, Adam S. Asch, MD, Manish R. Patel, MD, Jay Yang, MD, Alireza Eghtedar, MD, Gautam M. Borthakur, MD, Julie Charlton, PhD, Alexander MacDonald, MSc-PhD, Anna Korzeniowska, MD, Elizabeth Sainsbury, BSc, Donald K. Strickland, MD, Suzanne Jones, PharmD, Philip Overend, MSc, Carrie A. Adelman, PhD, Giulia Fabbri, MD PhD, Jon Travers, PhD, Simon Smith, PhD, J. Elizabeth Pease, PhD, Jan Cosaert, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3919.
https://doi.org/10.1182/blood-2019-130635
Published: 2019
Journal Articles

Phase 1 Dose Escalation and Expansion Study to Determine Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the BET Inhibitor FT-1101 As a Single Agent in Patients with Relapsed or Refractory Hematologic Malignancies

Manish R. Patel, MD, Guillermo Garcia-Manero, MD, Ronald Paquette, MD, Shira Dinner, MD, William B. Donnellan, MD, Michael R. Grunwald, MD, Maria D Ribadeneira, PhD, Patricia Schroeder, Julie Brevard, Lindsey Wilson, Jennifer Sweeney, Patrick Kelly, MD, Jeffrey E. Lancet, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3907.
https://doi.org/10.1182/blood-2019-124741
Published: 2019
Journal Articles

SEL120 - a First-in-Class CDK8/19 Inhibitor As a Novel Option for the Treatment of Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome - Data from Preclinical Studies and Introduction to a Phase Ib Clinical Trial

Gautam M. Borthakur, MD, William B. Donnellan, MD, Scott R. Solomon, MD, Camille Abboud, MD, Aziz Nazha, MD, Milena Mazan, PhD, Michal Mikula, MD PhD, Eliza Majewska, PhD, Katarzyna Wiklik, PhD, Aniela Golas, PhD, Marcus Järås, PhD, Marion Chapellier, PhD, Anna Polak, PhD, Arkadiusz Bialas, PhD, Renata Windak, PhD, Jerzy Ostrowski, Prof., MD PhD, Przemyslaw Juszczynski, Prof., MD PhD, Pawel Chrom, MD PhD, Tomasz Rzymski, PhD, Krzysztof Brzózka, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2651.
https://doi.org/10.1182/blood-2019-127835
Published: 2019
Journal Articles

A Phase I/II, Open-Label, Multicentre 2-Part Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticle As Monotherapy or in Combination in Treatment-Naïve or Relapsed/Refractory Acute Myeloid Leukaemia/Myelodysplastic Syndrome Patients Not Eligible for Intensive Induction Therapy

William B. Donnellan, MD, Ehab L. Atallah, MD, Adam S. Asch, MD, Manish R Patel, MD, Julie Charlton, Alexander MacDonald, Elena Young, Elizabeth Sainsbury, Donald Strickland, MD, Suzanne Jones, PharmD, Philip Overend, Carrie A. Adelman, Jon Travers, PhD, Simon Smith, PhD, J. Elizabeth Pease, PhD, Wolfram Brugger, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4064.
https://doi.org/10.1182/blood-2018-99-118465
Published: 2018
Journal Articles

Phase 1/1b Study of the Stapled Peptide ALRN-6924, a Dual Inhibitor of MDMX and MDM2, As Monotherapy or in Combination with Cytarabine for the Treatment of Relapsed/Refractory AML and Advanced MDS with TP53 Wild-Type

David A Sallman, MD, Uma Borate, MD, Elizabeth H. Cull, MD, William B. Donnellan, MD, Rami S. Komrokji, MD, Ulrich G. Steidl, MD PhD, Maria M Corvez, Marie Payton, MBA, D. Allen Annis, PhD, Dawn Pinchasik, MD, Manuel Aivado, MD PhD, Amit Verma, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4066.
https://doi.org/10.1182/blood-2018-99-118780
Published: 2018
Journal Articles

PD-L1 Blockade with Atezolizumab in Higher-Risk Myelodysplastic Syndrome: An Initial Safety and Efficacy Analysis

Aaron T. Gerds, MDMS, Bart L Scott, MD, Peter L Greenberg, MD, Samer K. Khaled, MD, Tara L Lin, MD, Daniel A Pollyea, MD, Amit Verma, MD, Monique Dail, Cherie Green, Connie Ma, Bruno C Medeiros, Patrick Phuong, Michael Wenger, Mark Yan, William B. Donnellan, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 466.
https://doi.org/10.1182/blood-2018-99-118577
Published: 2018
Journal Articles

Ivosidenib (AG-120) Induced Durable Remissions and Transfusion Independence in Patients with IDH1-Mutant Untreated AML: Results from a Phase 1 Dose Escalation and Expansion Study

Gail J. Roboz, MD, Courtney D. DiNardo, MDMSc, Eytan M. Stein, MD, Stephane de Botton, MD PhD, Alice S. Mims, MD, Gabrielle T. Prince, MD, Jessica K. Altman, MD, Martha L. Arellano, MD, William B. Donnellan, MD, Harry P. Erba, MD PhD, Gabriel N. Mannis, MD, Daniel A Pollyea, MD, Anthony S. Stein, MD, Geoffrey L. Uy, MD, Justin M. Watts, MD, Amir T. Fathi, MD, Hagop M. Kantarjian, MD, Martin S. Tallman, MD, Sung Choe, PhD, David Dai, PhD, Bin Fan, PhD, Hongfang Wang, PhD, Vickie Zhang, PhD, Katharine E. Yen, PhD, Stephanie M. Kapsalis, OTR, Denice Hickman, RN, Hua Liu, PhD, Samuel V. Agresta, MD, Bin Wu, PhD, Eyal C. Attar, MD, Richard M. Stone, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 561.
https://doi.org/10.1182/blood-2018-99-110595
Published: 2018
Journal Articles

Updated Phase 1 Results of Zuma-3: Kte-C19, an Anti-CD19 Chimeric Antigen Receptor T Cell Therapy, in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia

William G. Wierda, MD PhD, Michael R. Bishop, MD, Olalekan O. Oluwole, MBBS, MPH, Aaron C. Logan, MD PhD, Maria R. Baer, MD, William B. Donnellan, MD, Kristen M. O'Dwyer, MD, Januario E. Castro, MD, Gary J. Schiller, MD, Houston Holmes, MD, Mehrdad Abedi, MD, Armin Ghobadi, MD, Martha L. Arellano, MD, Adriana K. Malone, MD, John M. Pagel, MD PhD, Armen Mardiros, PhD, Tong Shen, MS, Remus Vezan, MD PhD, Rajul K. Jain, MD, Bijal D. Shah, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 897.
https://doi.org/10.1182/blood-2018-99-111531
Published: 2018
Journal Articles

A Phase 1b Study of Vadastuximab Talirine As Maintenance and in Combination with Standard Consolidation for Patients with Acute Myeloid Leukemia (AML)

Jay Yang, MD, Farhad Ravandi, MD, Anjali Advani, MD, Sumithira Vasu, MBBS, Roland B. Walter, MD PhD, Stefan Faderl, MD, Anthony S. Stein, MD, Harry P. Erba, MD PhD, Amir T. Fathi, MD, William B. Donnellan, MD, Moshe Y Levy, MD, Scott E. Smith, MD PhD, Brent L. Wood, MD PhD, Eric J. Feldman, MD, Jenna L Voellinger, PhD, Michael B. Maris, MD
Journal: Blood
Blood (2016) 128 (22): 340.
https://doi.org/10.1182/blood.V128.22.340.340
Published: 2016
Journal Articles

A Phase 1b Study of Vadastuximab Talirine in Combination with 7+3 Induction Therapy for Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

Harry P. Erba, MD PhD, Moshe Y Levy, MD, Sumithira Vasu, MBBS, Anthony S. Stein, MD, Amir T. Fathi, MD, Michael B. Maris, MD, Anjali Advani, MD, Stefan Faderl, MD, Scott E. Smith, MD PhD, Brent L. Wood, MD PhD, Roland B. Walter, MD PhD, Jay Yang, MD, William B. Donnellan, MD, Eric J. Feldman, MD, Jenna L Voellinger, PhD, Farhad Ravandi, MD
Journal: Blood
Blood (2016) 128 (22): 211.
https://doi.org/10.1182/blood.V128.22.211.211
Published: 2016
Journal Articles

Results from Ongoing Phase 2 Trial of SL-401 As Consolidation Therapy in Patients with Acute Myeloid Leukemia (AML) in Remission with High Relapse Risk Including Minimal Residual Disease (MRD)

Andrew A. Lane, MD PhD, Kendra L. Sweet, MD, Eunice S. Wang, MD, William B. Donnellan, MD, Roland B. Walter, MD PhD, Anthony S. Stein, MD, David A Rizzieri, MD, Hetty E. Carraway, MD MBA, Ioannis Mantzaris, MD, Thomas Prebet, MD PhD, Michael B. Maris, MD, Stefan Faderl, MD, Dale L. Bixby, MD PhD, Janice Chen, PhD, Ross Lindsay, PhD, Shay Shemesh, MA, Christopher L. Brooks, PhD, Richard M. Stone, MD, Hagop M. Kantarjian, MD, Elias J. Jabbour, MD, Marina Konopleva, MD PhD
Journal: Blood
Blood (2016) 128 (22): 215.
https://doi.org/10.1182/blood.V128.22.215.215
Published: 2016
Journal Articles

Clinical Utility of High-Throughput and Complimentary Genomic Tumor Profiling in Hematologic Malignancies

Zeqiang Ma, PhD, Jason Gottwals, Hao Ho, MDPhD, Kristina J. Fasig, MD, Heather Rietz, MD, Taylor Hartley, MD, Vladimir Kravstov, MD, David C. Spence, MD, Dan Connor, MD, Ron Turnicky, DO, James Prescott, PhD, Patrick Lennon, PhD, Malini Sathanoori, PhD, Ian W. Flinn, MD PhD, Jesus G. Berdeja, MD, William B. Donnellan, MD, Scott Wheeler, PhD, Christopher Coldren, PhD, Pranil Chandra, DO, Sandeep Mukherjee, PhD, Terence Casey, MD
Journal: Blood
Blood (2015) 126 (23): 1388.
https://doi.org/10.1182/blood.V126.23.1388.1388
Published: 2015